Posted On: 08/22/2014 11:42:50 AM
Post# of 30066
3/26/14
DL: Yes. But let me add that we also have frequent and intensive interactions with large pharmaceutical companies working in the neuroscience area. That actually complements what we do on the private, micro-, small- and mid-cap fronts. We don't work directly for large pharmas like Novartis AG (NVS:NYSE), Roche Holding AG (RHHBY:OTCQX), Sanofi SA (SNY:NYSE) or Eli Lilly and Co. (LLY:NYSE), but we definitely know what's going on, and we know the right people to contact in those organizations about any particular R&D or business development opportunity.
Presentations
1. To Sonofi-Aventis, South San Francisco, CA; September 21, 2011
MANF: A Protein Biologic with Multiple Indications; A Non-confidential Presentation to Sonofi-Aventis
By John Commissiong
Read more: http://investorshangout.com/post/view?id=1887...z3B8VascU1
DL: Yes. But let me add that we also have frequent and intensive interactions with large pharmaceutical companies working in the neuroscience area. That actually complements what we do on the private, micro-, small- and mid-cap fronts. We don't work directly for large pharmas like Novartis AG (NVS:NYSE), Roche Holding AG (RHHBY:OTCQX), Sanofi SA (SNY:NYSE) or Eli Lilly and Co. (LLY:NYSE), but we definitely know what's going on, and we know the right people to contact in those organizations about any particular R&D or business development opportunity.
Presentations
1. To Sonofi-Aventis, South San Francisco, CA; September 21, 2011
MANF: A Protein Biologic with Multiple Indications; A Non-confidential Presentation to Sonofi-Aventis
By John Commissiong
Read more: http://investorshangout.com/post/view?id=1887...z3B8VascU1
(0)
(0)
